Author, Year | N | REBOA Use (min) | Follow Up (Hours) | Survival (%) | End Study Values of Ischemic Markers and Significance vs. Control | ||||
---|---|---|---|---|---|---|---|---|---|
Lactate | Potassium | Troponin | Creatinine | pH | |||||
Avaro, et al. 2011 [83] | 8 (25) | 60 | 1 | 20 | 9.59 ± 1.19 | 6.08 ± 0.44 | – | – | – |
Markov, et al. 2013 [82] | 6 (24) | 30 | 54 | 100 | 1.5m | 3.8 ± 0.4 | 0.04 ± 0.05 | 1.1 ± 0.4 | – |
6 (24) | 90 | 54 | 100 | 1.5m | 4.0 ± 0.5 | 0.16 ± 0.30 | 1.2 ± 0.2 | – | |
Scott, et al. 2013 [84] | 16 | 60 | 48 | NR | 0.63 (0.21)c | 7.66 (1.45)c * | – | 1.7 (0.8)c | 7.4c |
0.62 (0.08)d | 6.10 (3.27)d * | – | 1.5 (0.2)d | 7.4d | |||||
Morrison, et al. 2014 [81] | 8 (24) | 60 | 48 | 87.3 | 9.0 ± 4.5 | 5.2 ± 0.8 * | – | 2.6 ± 0.5 * | 7.22 ± 1.45 |
Morrison, et al. 2014 [81] | 6 (20) | 30 | 48 | 100 | 0.5 ± 0.1 | – | 0.28 ± 0.24 | – | 7.46 ± 0.02 |
8 (20) | 60 | 48 | 100 | 0.6 ± 0.2 | – | 0.44 ± 0.38 | – | 7.40 ± 0.10 | |
6 (20) | 90 | 48 | 100 | 0.6 ± 0.1 | – | 0.38 ± 0.49 | – | 7.43 ± 0.04 | |
Tibbets, et al. 2018 [85] | 12 (18) | 45 | 4.75 | 100 | 6h, m | – | – | 1.7 ± 0.1h, m | 7.4h, m |
3i, m | – | – | 1.8 ± 0.1i, m | 7.5i, m | |||||
Williams, et al. 2018 [86] | 6 (12) | 45 | 4.75 | NR | 5.2 (3.7–6.8)j * | – | – | 5.2 (3.7–6.8)j | – |
3.0 (2.4–3.6)k * | – | – | 1.66 (1.63–1.69)k | – | |||||
Beyer, et al. 2019 [77] | 6 (18) | 45 | 4.75 | NR | – | – | 6.26 ± 5.35 * | – | – |
8 (21) | 60 | 6 | 37.5 | 19.2 ± 2.3 * | 5.1 ± 0.21 | 58.1 ± 28.6 * | 4.0 ± 0.37 * | – | |
Kuckelman, et al. 2019 [88] | 5 (20) | 60 | 2 | 20 | 12.8 | – | – | 1.8 | 7.22 |
Sadeghi, et al. 2020 [89] | 6 (18) | 30 | 3 | 100 | 5.4 (2.4–8.4) | – | NR | – | 7.5 |
Singer, et al. 2020 [90] | 20 | 37a | 4b | NR | 10f | 5f | – | – | ~ 7.4f |
7g | 5.5g | – | – | ~ 7.4g | |||||
Yamashiro, et al. 2020 [91] | 6 (11) | 30 | 3 | 100 | 3.4 ± 0.6 | – | – | 1.4 ± 0.1 | 7.43 ± 0.02 |
Yamashiro, et al. 2020 [91] | 3 (12) | 30 | 4 | 66.6 | NR | – | – | 1.2 | NR |
5 (12) | 60 | 4 | 60 | 5.7 * | – | – | 1.7 * | 7.2 * |